LGVN Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: Longeveron

Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)

8 days ago - By: Longeveron

Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy

16 days ago - By: Benzinga - Mentions: ACET RIGL TEM AKTX ...

12 Health Care Stocks Moving In Tuesday's After-Market Session

16 days ago - By: Longeveron

Longeveron® Announces Third Quarter 2025 Financial Results and Provides Business Update

17 days ago - By: Benzinga - Mentions: KURA SEE HRMY FOLD ...

Earnings Scheduled For November 4, 2025

3 months ago - By: Longeveron

Longeveron Announces Up To $17.5 Million Public Offering

23 days ago - By: Longeveron

Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

24 days ago - By: Longeveron

Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR’s BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect

2 months ago - By: Longeveron

Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

2 months ago - By: Longeveron

George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors

2 months ago - By: Longeveron

Longeveron® to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa

3 months ago - By: Longeveron

Longeveron® Announces Key Leadership Updates

3 months ago - By: Longeveron

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

3 months ago - By: The Motley Fool

Longeveron Posts 32% Revenue Drop in Q2

3 months ago - By: Longeveron

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update

3 months ago - By: Longeveron

Longeveron Announces Closing Of Up To $17.5 Million Public Offering

4 months ago - By: Longeveron

Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025

4 months ago - By: Longeveron

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

5 months ago - By: Longeveron

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)

5 months ago - By: Longeveron

Longeveron® Appoints Than Powell as Chief Business Officer

5 months ago - By: Longeveron

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

5 months ago - By: Longeveron

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

6 months ago - By: Longeveron

Longeveron® to Attend BIO International Convention 2025

6 months ago - By: Longeveron

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

6 months ago - By: Longeveron

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

7 months ago - By: Longeveron

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

7 months ago - By: Longeveron

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

7 months ago - By: Longeveron

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

7 months ago - By: Longeveron

Longeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025

8 months ago - By: Longeveron

LONGEVERON INC-A (LGVN) Stock News

LGVN Latest News, Press Relases and Analysis

Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)

Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy

12 Health Care Stocks Moving In Tuesday's After-Market Session

Longeveron® Announces Third Quarter 2025 Financial Results and Provides Business Update

Earnings Scheduled For November 4, 2025

Longeveron Announces Up To $17.5 Million Public Offering

Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR’s BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect

Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors

Longeveron® to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa

Longeveron® Announces Key Leadership Updates

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Longeveron Posts 32% Revenue Drop in Q2

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update

Longeveron Announces Closing Of Up To $17.5 Million Public Offering

Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)

Longeveron® Appoints Than Powell as Chief Business Officer

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Longeveron® to Attend BIO International Convention 2025

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Longeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025

Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease